Capital Advantage, Inc. Novartis Ag Transaction History
Capital Advantage, Inc.
- $664 Million
- Q4 2025
A detailed history of Capital Advantage, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Capital Advantage, Inc. holds 1,846 shares of NVS stock, worth $242,841. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,846
Previous 1,757
5.07%
Holding current value
$242,841
Previous $225,000
7.56%
% of portfolio
0.04%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding NVS
# of Institutions
1,600Shares Held
137MCall Options Held
1.53MPut Options Held
2.22M-
Dodge & Cox San Francisco, CA10.6MShares$1.39 Billion0.78% of portfolio
-
Primecap Management CO Pasadena, CA9.34MShares$1.23 Billion0.95% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.84MShares$1.16 Billion0.25% of portfolio
-
Morgan Stanley New York, NY7.73MShares$1.02 Billion0.06% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa7.24MShares$952 Million0.34% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $283B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...